Floatz Rating
CCC54/100
Confidence
Indicative
Sponsor
TransThera Sciences (Nanjing), Inc.
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07328919CT.gov Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Intrahepatic Cholangiocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tinengotinib (this asset) | TransThera Sciences (Nanjing), Inc. | P3 | CCC · 54 |
| Nivolumab | Virogin Biotech Canada Ltd | P2 | BB |
| Durvalumab | West China Hospital | P2 | BB |
| Cis-Diamminedichloroplatinum Ii | Shanghai 6th People's Hospital | P2 | BB |
| Atezolizumab | National Cancer Institute (NCI) | P2 | B |
| Irinotecan | Tianjin Medical University Cancer Institute and Hospital | P3 | B |
| Ipilimumab | TriSalus Life Sciences, Inc. | P2 | B |
| Lenvatinib | Tianjin Medical University Cancer Institute and Hospital | P2 | B |
| Fluorouracilum | Tianjin Medical University Cancer Institute and Hospital | P3 | B |
+42 more in the Intrahepatic Cholangiocarcinoma cohort
Other indications for Tinengotinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cholangiocarcinoma | — | P3 | B · 59 |
| Triple-Negative Breast Carcinoma | — | P1/2 | B · 57 |
| Cancer | — | P1/2 | CCC · 55 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tinengotinib in Intrahepatic Cholangiocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tinengotinib-intrahepatic-cholangiocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →